| An SI Board Since June 2014 |
| Posts |
SubjectMarks |
Bans |
Symbol |
| 9 |
1 |
0
|
GNSZ |
|
2511 N Loop 1604 W
Suite 204
San Antonio, TX 78258
Phone: 210-479-8112
Email: info@genspera.com
Website: genspera.com
Craig Dionne President, CEO, CFO
Russell Richerson COO, Secretary
| | 
| Shares Outstanding | 27,392,100 | a/o Mar 09, 2014 | | Float | Not Available | | Authorized Shares | 80,000,000 | a/o Jun 30, 2009 |
Latest Report Mar 31, 2014 10-Q
CIK 0001421204
Fiscal Year End 12/31
|
Business Description
We are a biotechnology company focused on the discovery and development of pro-drug cancer therapeutics, an emerging medical science. A pro-drug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. We were incorporated as a Delaware corporation in 2003.
GenSpera Inc. (GenSpera) is a development-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including prostate, liver, brain and other cancers. A prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. The Company has four prodrug candidates: G-202, G-114, G-115 and G-301. The Company's primary focus is the clinical development of its compound, G-202, a therapeutic agent with a mechanism of action. G-202 is in Phase II Clinical Trial. G-114 is validated efficacy in pre-clinical animal models. Pilot toxicology is completed for G-115. G-301 is validated efficacy in pre-clinical animal models. The Company is also conducting a Phase II clinical trial to test the utility of G-202 in patients with hepatocellular carcinoma (liver cancer). As of March 27, 2013, it treated one patient in this Phase II trial.
|
GenSpera harnesses a novel biomedical technology platform to deliver a powerful toxin directly to tumors
- Phase II clinical trials for lead compound, G-202, are underway in two indications:
- Hepatocellular carcinoma, or liver cancer
- Glioblastoma, or brain cancer
Experienced and motivated team drives the process: Core team has extensive experience in successfully identifying and bringing oncology treatments to the clinic. Scientific Advisory Board is comprised of leading researchers who are both the inventors of the technology and shareholders. Technology platform supports the development of a suite of drugs targeted at different cancers, as well as other applications such as imaging. Over 15 years of research at Johns Hopkins Medical Center and other renowned research centers, including the University of Copenhagen. Strong intellectual property portfolio No milestones or royalty payments owed to third parties. Leverage the team's passion and expertise in identifying promising treatments and bringing them to the clinic.
|  |
|
|
|
